Table 4 Summarized results of cohort studies.

From: Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review

Outcome

Time point

No. of included studies

Sample size of PEG-rhGH group

Sample size of short-term rhGH group

Mean difference (95%CI)

p value

Change in height (SDS)

6 m

2

69

79

−0.02 (−0.24, 0.19)

0.82

 

12 m

3

94

126

0.19 (0.03, 0.35)

0.02

 

24 m

1

38

47

0.14 (−0.19, 0.47)

0.41

Change in HV (cm/y)

6 m

2

69

79

−0.23 (−0.98, 0.52)

0.55

 

12 m

3

94

126

0.21 (−0.22, 0.63)

0.34

 

24 m

1

38

47

0.38 (−0.30, 1.06)

0.28

IGF-1 (SDS)

6 m

2

69

79

0.40 (0.04, 0.76)

0.03

 

12 m

1

49

49

0.17 (−0.41, 0.75)

0.56

 

24 m

1

38

47

0.57 (0.02, 1.12)

0.04

Change in IGF-1 (SDS)

6 m

2

69

79

0.39 (0.04, 0.74)

0.03

 

12 m

2

69

79

0.46 (0.10, 0.81)

0.01

 

24 m

1

38

47

0.61 (0.09, 1.13)

0.02

Change in IGF-1 (ng/mL)

12 m

1

25

47

20.54 (9.17, 31.91)

0.0004

Back to article page